No products in the cart.
Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.
| Quantity | 100mg, 500mg, 1 g |
|---|
Be the first to review “Rebastinib (DCC-2036)”
Related products
*Sales Promotion for 2022
$400.00 – $650.00
New Research Chemicals
$350.00 – $550.00
New Research Chemicals
$500.00 – $3,000.00
New Research Chemicals
$135.00 – $500.00
New Research Chemicals
$100.00 – $450.00
New Research Chemicals
$300.00 – $500.00
New Research Chemicals
$100.00 – $500.00
New Research Chemicals
$300.00 – $5,000.00
Reviews
There are no reviews yet.